{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T00:52:26Z","timestamp":1790988746765,"version":"4.1.0"},"reference-count":16,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2009,1,1]],"date-time":"2009-01-01T00:00:00Z","timestamp":1230768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,1,1]],"date-time":"2009-01-01T00:00:00Z","timestamp":1230768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2009,1]]},"DOI":"10.3816\/cgc.2009.n.004","type":"journal-article","created":{"date-parts":[[2009,2,12]],"date-time":"2009-02-12T21:01:42Z","timestamp":1234472502000},"page":"24-27","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":128,"title":["Phase I Study Combining Treatment with Temsirolimus and Sunitinib Malate in Patients with Advanced Renal Cell Carcinoma"],"prefix":"10.3816","volume":"7","author":[{"given":"Premal H.","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peggy L.","family":"Senico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael E.","family":"Curiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Motzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.3816\/CGC.2009.n.004_bib1","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1016\/S0140-6736(07)61874-1","article-title":"Targeted drugs for metastatic renal cell carcinoma","volume":"370","author":"Motzer","year":"2007","journal-title":"Lancet"},{"key":"10.3816\/CGC.2009.n.004_bib2","doi-asserted-by":"crossref","first-page":"764s","DOI":"10.1158\/1078-0432.CCR-06-1975","article-title":"Opportunities and obstacles to combination targeted therapy in renal cell cancer","volume":"13","author":"Sosman","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CGC.2009.n.004_bib3","doi-asserted-by":"crossref","first-page":"7215","DOI":"10.1158\/1078-0432.CCR-06-2254","article-title":"Targeting von Hippel-Lindau pathway in renal cell carcinoma","volume":"12","author":"Patel","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CGC.2009.n.004_bib4","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1158\/1078-0432.CCR-06-2798","article-title":"The mammalian target of rapamycin signaling pathway: twists and turns in the road to cancer therapy","volume":"13","author":"Abraham","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CGC.2009.n.004_bib5","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1128\/MCB.24.1.200-216.2004","article-title":"mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1\/eukaryotic translation initiation factor 4E","volume":"24","author":"Fingar","year":"2004","journal-title":"Mol Cell Biol"},{"key":"10.3816\/CGC.2009.n.004_bib6","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ccr.2007.05.008","article-title":"Defining the role of mTOR in cancer","volume":"12","author":"Guertin","year":"2007","journal-title":"Cancer Cell"},{"key":"10.3816\/CGC.2009.n.004_bib7","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1358\/dot.2007.43.10.1148059","article-title":"Temsirolimus","volume":"43","author":"Ma","year":"2007","journal-title":"Drugs Today (Barc)"},{"key":"10.3816\/CGC.2009.n.004_bib8","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa066838","article-title":"Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma","volume":"356","author":"Hudes","year":"2007","journal-title":"N Engl J Med"},{"key":"10.3816\/CGC.2009.n.004_bib9","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1200\/JCO.2006.06.3602","article-title":"Sunitinib: from rational design to clinical efficacy","volume":"25","author":"Chow","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.3816\/CGC.2009.n.004_bib10","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N Engl J Med"},{"key":"10.3816\/CGC.2009.n.004_bib11","series-title":"Torisel [package insert]","year":"2007"},{"key":"10.3816\/CGC.2009.n.004_bib12","series-title":"Sutent [package insert]","year":"2007"},{"key":"10.3816\/CGC.2009.n.004_bib13","unstructured":"Boni J, Burns J, Hug B, et al. mTOR inhibition following a single intravenous infusion of temsirolimus in healthy individuals. Presented at: AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; San Francisco, CA; October 22-27, 2007."},{"key":"10.3816\/CGC.2009.n.004_bib14","doi-asserted-by":"crossref","first-page":"3958","DOI":"10.1200\/JCO.2006.10.5916","article-title":"Temsirolimus plus interferon alfa phase I trial in patients with advanced renal cell carcinoma","volume":"25","author":"Motzer","year":"2007","journal-title":"J Clin Oncol"},{"issue":"18 suppl","key":"10.3816\/CGC.2009.n.004_bib15","first-page":"243s","article-title":"Phase I\/II trial of CCI-779 and bevacizumab in stage IV renal cell carcinoma: phase I safety and activity results","volume":"25","author":"Merchan","year":"2007","journal-title":"J Clin Oncol"},{"issue":"20 suppl","key":"10.3816\/CGC.2009.n.004_bib16","first-page":"259s","article-title":"Phase I trial of bevacizumab plus sunitinib in patients with metastatic renal cell carcinoma","volume":"26","author":"Feldman","year":"2008","journal-title":"J Clin Oncol"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767311700106?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767311700106?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:20:39Z","timestamp":1761564039000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767311700106"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,1]]}},"alternative-id":["S1558767311700106"],"URL":"https:\/\/doi.org\/10.3816\/cgc.2009.n.004","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2009,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase I Study Combining Treatment with Temsirolimus and Sunitinib Malate in Patients with Advanced Renal Cell Carcinoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.3816\/CGC.2009.n.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}